Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Eli Lilly and Company is conducting a significant clinical study titled A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight. This study aims to evaluate the effectiveness and safety of the drug Orforglipron in individuals with moderate-to-severe obstructive sleep apnea (OSA) who are also obese or overweight. The study is divided into two parts: one for participants who cannot or do not want to use positive airway pressure (PAP) therapy and another for those who are already on PAP therapy.
The intervention being tested is Orforglipron, an oral medication designed to treat OSA in overweight or obese individuals. The study also includes a placebo group for comparison.
This interventional study follows a randomized, double-blind, placebo-controlled design with a parallel intervention model. The primary purpose is treatment, and both participants and investigators are blinded to the treatment assignments.
The study began on October 22, 2024, with the latest update submitted on June 24, 2025. These dates are crucial as they mark the study’s progress and the timeline for potential results.
The outcome of this study could significantly impact Eli Lilly’s stock performance and investor sentiment, especially if Orforglipron proves effective. This could position Eli Lilly favorably against competitors in the sleep disorder treatment market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.